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OBJECTIVES: To evaluate the effectiveness of pramipexole
treatment in patients with primary Restless Legs Syndrome (RLS)
and, secondarily, the effect on work productivity impairment
associated with RLS. METHODS: This was an open-label, 12
week-prospective, non-controlled, non-interventional trial in
patients with primary moderate to severe RLS being treated with
the non-ergot dopamine agonist pramipexole by general practi-
tioners and internists across Germany under routine conditions.
Work productivity impairment was assessed by the Work Pro-
ductivity and Activity Impairment Questionnaire (WPAI), RLS
severity was measured by the International RLS Study Group
Rating Scale (IRLS). RESULTS: A total of 2,546 patients suffer-
ing from moderate to severe RLS were evaluated at 904 sites. The
mean age of the patients was 64.8 years and 67.8% were female.
Median treatment duration was 92 days. Patients were starting
with a median initial pramipexole dose of 0.088 mg/d, were
ﬂexibly titrated and had a ﬁnal maintenance dose of 0.35 mg/d.
RLS severity was signiﬁcantly improved: IRLS mean score was
25.7 at baseline and 9.6 at the ﬁnal visit. From the total popu-
lation 539 patients (21.2%) were in paid labour. The mean age of
this sub-population was 52.1 years; 58.1% were female. Impair-
ment while working due to RLS was reduced by 30% (median) in
a subgroup of 436 patients, who reported impairment at base-
line. In 162 patients reporting ‘Missing from work due to health
problems’ at baseline, a 6.1 hours/week (mean) reduction at the
ﬁnal visit was assessed by the WPAI, which translates into an
average reduction in productivity loss for working RLS patients
of €1642 in Germany. CONCLUSION: Pramipexole showed to
be highly effective in the treatment of RLS in routine care, as
substantiated by IRLS. Work productivity was substantially
increased and impairment while working due to RLS-symptoms
was reduced in patients being in paid labour.
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OBJECTIVES: To evaluate the efﬁcacy of zoledronic acid relative
to other anti-resorptive interventions regarding the prevention of
vertebral fractures in postmenopausal women with osteoporosis.
METHODS: Twelve randomized placebo controlled trials inves-
tigating the effects of zoledronic acid (1 study), alendronate (3),
risedronate (2), ibandronate (1), etidronate (1), calcitonin (1),
ralixofene (1), or strontium ranelate (2) in terms of fractures with
a follow-up of 3 years (or 2 years if used for registration pur-
poses) were identiﬁed with a systematic literature search. The
endpoint of interest was morphometric vertebral fractures.
Results of all trials were analyzed simultaneously with a Bayesian
mixed treatment comparison (MTC). MTC is an extension of
traditional meta-analysis by including multiple different pair-
wise comparisons across the range of different interventions.
With MTC the relative treatment effect of one intervention to
another can be obtained in the absence of head-to-head evidence.
In contrast to a frequentist approach, a Bayesian analysis allows
for direct probabilistic inferences. Outcomes were analyzed using
a random effects model. RESULTS: There is a 73.6% probability
that zoledronic acid shows the greatest reduction in vertebral
fractures of all interventions compared, followed by etidronate
(23.2% probability) and ibandronate (1.8%). Zoledronic acid
showed an OR of 0.28 (95% Credible Interval 0.19–0.40) rela-
tive to placebo, an OR of 0.62 relative to etidronate, and an OR
of 0.55 relative to ibandronate. Corresponding probabilities that
zoledronic provides a greater vertebral risk reduction are 99.9%,
79.6%, and 98.9% compared to placebo, etidronate, and iban-
dronate, respectively. Similar comparisons are under investiga-
tion for other fracture endpoints. CONCLUSION: Of the
available treatments for osteoporosis, zoledronic acid is one of
the treatments that provide greatest fracture risk reductions in
general. Furthermore zoledronic acid showed greatest reductions
regarding vertebral fractures.
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OBJECTIVES: Regarding intracapsular femoral neck fractures,
the main focus of research is the correlation between fracture-
related complications and prognostic factors. The purpose of this
study was to evaluate the correlation between complications
required surgery (fracture-related treatment) and, among others,
several less extensively investigated prognostic factors (day of
surgery, co-morbidities, hospital type) in a 2-year period follow-
ing internal ﬁxation in young adults with intracapsular femoral
neck fracture. METHODS: Retrospective analysis of femoral
neck fractures occurred in Hungary in 2000, based on data
obtained from the National Health Fund Administration. The
data were validated and completed by a questionnaire carried out
Abstracts A393
